More research is needed into estimating risk in heart failure and in communicating prognostic information to patients 
E
stimating prognosis is endorsed by recent clinical guidelines as a key element of the management of heart failure. 1 2 How this is to be done is less clear. Heart failure follows a variable clinical course, and as many as one half of patients will die suddenly rather than dying of progressive heart failure. 3 The predictability of death may therefore be lower than in other conditions. The challenge of identifying clinical variables consistently associated with mortality has been summarised by Cowburn and colleagues. 4 Many of the published studies are small, and include highly selected patient populations, with different variables recorded in each dataset. Differences in the way measurements are made-for example, in the assessment of left ventricular systolic function-and the close correlation between many variables add further complexity. Also, it should not be assumed that the same variables will be associated with mortality in the early phases of heart failure as well as in the later phases. The recent rise in the use of β blockade may make the conclusions drawn from earlier studies less relevant to modern practice. From the statistical viewpoint, the methodology of how best to use available data and to validate the derived risk equations is rapidly evolving. 5 6 Writing in this issue of Heart, Bouvy and colleagues are to be congratulated on recognising the need for a simple, but robust, prognostic scoring system for patients with heart failure. 7 Simple models are not necessarily of less value than more complex models. 8 Indeed, they may be closer to real life practice. Many patients with heart failure are not exposed to "high tech" investigations. For example, the Euroheart heart failure survey reported that less than 5% of patients with heart failure who come into contact with a hospital undergo a cardiopulmonary exercise test. Although maximal oxygen consumption and other measures of exercise performance may be useful predictors of survival such data are unlikely to be available for most patients.
A CLINICAL APPROACH
In day-to-day practice the process of arriving at a diagnosis is hierarchical. The physician proceeds by gathering information from history, then physical examination, supplemented by increasingly complex tests before reaching a point where the diagnosis in question is considered either very likely or very unlikely. Bouvy and colleagues adopt a similar approach to estimating the probability of survival. 7 The initial statistical model uses only information from the clinical history. They then add features from physical examination and the results of simple laboratory investigations. Only where there is good evidence that more sophisticated tests or less readily available information add to the prediction of risk do they include these. In addition, they recognise that dropping patients with missing data introduces bias and reduces the power of their model. Instead they impute values for those that are missing, an increasingly accepted approach that if done properly can be of great value. 5 The Bouvy score is practical and potentially useful in a wide range of clinical and health care settings. The information required to derive the score is age, sex, New York Heart Association (NYHA) class, history of diabetes mellitus, history of renal dysfunction, weight, blood pressure, ankle oedema, and use of β blockers. Statistical tests for "goodness-of-fit" of the model (how well the predicted mortality in the model accords with the observed mortality) appear satisfactory. The ability of the score to discriminate between those who died and those who survived during 18 months of follow up is very good (area under the receiver operating characteristics curve is 0.84, 95% confidence interval 0.77 to 0.90). This compares favourably with many diagnostic and prognostic scoring systems generally accepted in other disease areas. 9 
WILL THE SCORE WORK IN PRACTICE?
A scoring system is only of clinical value if it works when transferred into a population other than the one from which it was derived. Bouvy and colleagues recruited a cohort of patients similar to those reported from population based studies 10 -the average age was 70 years, two thirds were female, and the single most common aetiology was coronary artery disease. Of note, a third of their patients were treated with a β blocker-a much higher proportion than in earlier published reports of prognostic variables. 4 However, the patients were recruited from a randomised clinical trial and may therefore not be truly representative of patients with heart failure. The results look promising, particularly as the component variables have been reported to be associated with survival in other studies. 4 11 External validation in another dataset is required and is underway.
THE FUTURE FOR RISK PREDICTION
Is it valuable to spend more research effort on developing better risk prediction equations for patients with heart failure? The evolving professional and societal consensus is that doctors should be more open with patients about all possible courses of action and the likely results of these actions. If a doctor does not communicate prognostic information to a patient they may be denying the patient an opportunity to make fully informed choices about their care. Inaccurate estimates of prognosis may distort a patient's choice of treatment and the trade-off that they may be willing to make between quality and quantity of life-a particularly important consideration for very elderly patients with heart failure. Most patients do not need a precise understanding of their prognosis to change their treatment preferences-studies involving patients with cancer suggest that merely telling a patient that they have at least a 10% probability of not surviving six months may make them substantially alter their treatment preferences. 12 Recent studies report that most people with heart failure do not have a discussion with health care professionals about the prognosis of their disease. 13 14 We owe it to our patients to develop tools that enable us to predict prognosis as precisely and as accurately as is biologically possiblerecognising that this will always be an inexact science. The communication of this information, and helping patients to arrive at a truly informed choice about their care, should be an integral part of clinical management.
A CHALLENGE FOR GUIDELINES AND PROFESSIONALS
At a more pragmatic level, doctors and other health care professionals need clear guidance on how to identify patients at particularly high or low risk. This should then trigger changes in care, with consideration of referral for appropriately aggressive or intensive therapy. Such treatment may best be delivered in another health care setting or by another health care professional. Clinical guidelines need to address these practical issues if they are to impact properly on the care of patients with heart failure. Estimating prognosis, talking with patients about these issues, and arriving at an appropriate management plan is a challenge. The work of Bouvy and colleagues 7 is a welcome step towards a more objective and rational approach. 
